Height Securities analyst Stefanie Miller thinks Philip Morris International (PM -2.2%) is likely to end up with FDA approval for its IQOS risk claim.
Miller says the advisory committee that ruled today was too "unprepared" and "inexperienced" to do anything but act as a roadblock. She also points out that the panel's recommendation is non-binding.
Philip Morris is looking for the modified risk tobacco product designation from the agency to help market IQOS products.
Previously: FDA rejects Philip Morris IQOS claims (Jan. 25)
Now read: Philip Morris: Is It Time To Quit? »
Subscribe for full text news in your inbox